The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 179: 1855-1863.
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, N.
Right arrow Articles by Matthay, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, N.
Right arrow Articles by Matthay, M. A.

Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1

Naveen Gupta2,*, Xiao Su*, Boris Popov{dagger}, Jae Woo Lee*, Vladimir Serikov{dagger} and Michael A. Matthay*

* Cardiovascular Research Institute, University of California, San Francisco, CA 94143; and {dagger} Children’s Hospital of Oakland Research Institute, Oakland, CA 94609

Recent in vivo and in vitro work suggests that mesenchymal stem cells (MSC) have anti-inflammatory properties. In this study, we tested the effect of administering MSC directly into the airspaces of the lung 4 h after the intrapulmonary administration of Escherichia coli endotoxin (5 mg/kg). MSC increased survival compared with PBS-treated control mice at 48 h (80 vs 42%; p < 0.01). There was also a significant decrease in excess lung water, a measure of pulmonary edema (145 ± 50 vs 87 ± 20 µl; p < 0.01), and bronchoalveolar lavage protein, a measure of endothelial and alveolar epithelial permeability (3.1 ± 0.4 vs 2.2 ± 0.8 mg/ml; p < 0.01), in the MSC-treated mice. These protective effects were not replicated by the use of further controls including fibroblasts and apoptotic MSC. The beneficial effect of MSC was independent of the ability of the cells to engraft in the lung and was not related to clearance of the endotoxin by the MSC. MSC administration mediated a down-regulation of proinflammatory responses to endotoxin (reducing TNF-{alpha} and MIP-2 in the bronchoalveolar lavage and plasma) while increasing the anti-inflammatory cytokine IL-10. In vitro coculture studies of MSC with alveolar macrophages provided evidence that the anti-inflammatory effect was paracrine and was not cell contact dependent. In conclusion, treatment with intrapulmonary MSC markedly decreases the severity of endotoxin-induced acute lung injury and improves survival in mice.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the National Institutes of Health Grant HL-51854 (to M.A.M.) and the California Institute of Regenerative Medicine Training Grant (to N.G.).

2 Address correspondence and reprint requests to Dr. Naveen Gupta, Cardiovascular Research Institute, University of California, San Francisco, HSW 825, 505 Parnassus Avenue, San Francisco, CA 94143-0130. E-mail address: naveen.gupta{at}ucsf.edu

3 Abbreviations used in this paper: ALI, acute lung injury; MSC, mesenchymal stem cell(s); GM, growth medium; BAL, bronchoalveolar lavage; MPO, myeloperoxidase; i.t., intratracheal(ly).




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667.
[Full Text] [PDF]


Home page
DiabetesHome page
R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh
Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes
Diabetes, July 1, 2008; 57(7): 1759 - 1767.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. Soupene, V. Serikov, and F. A. Kuypers
Characterization of an acyl-coenzyme A binding protein predominantly expressed in human primitive progenitor cells
J. Lipid Res., May 1, 2008; 49(5): 1103 - 1112.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
M. A. Matthay
Treatment of Acute Lung Injury: Clinical and Experimental Studies
Proceedings of the ATS, April 15, 2008; 5(3): 297 - 299.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
D. S. Krause
Bone Marrow-derived Cells and Stem Cells in Lung Repair
Proceedings of the ATS, April 15, 2008; 5(3): 323 - 327.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
N. F. Voelkel
Conference Summary
Proceedings of the ATS, April 15, 2008; 5(3): 354 - 357.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. A. Fowler, N. K. J. Adhikari, D. C. Scales, W. L. Lee, and G. D. Rubenfeld
Update in Critical Care 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 808 - 819.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.